Shares of kidney dialysis providers fell sharply Wednesday after Novo Nordisk said a study showed its Ozempic drug could delay the onset of kidney disease in diabetes patients. This latest development reinforces the far-reaching implications GLP-1 medications could have on a wide variety of conditions, from liver disease to sleep apnea to heart disease. Initially developed as a treatment for diabetes, the drugs have shown benefits for other conditions, most notably weight loss .
Companies that fill injectable pens administered to patients could win as drugmakers scramble to meet growing demand. That could prove a major boon for companies such as Catalent and Thermo Fisher Scientific , both of which have reportedly tapped manufacturing agreements with Novo Nordisk, according to Reuters . Catalent shares have only risen about 3% year to date, while Thermo Fisher's slumped a little more than 10%.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »
출처: mercnews - 🏆 88. / 68 더 많은 것을 읽으십시오 »